Register for our free email digests:
Value-Added Medicines
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sandoz Phases US Epinephrine Entry
Dr Reddy’s Growth Strategy Sets Sights On Six Spaces
Dr Reddy’s chief operating officer Erez Israeli says six key areas – the US, China, Russia, India, APIs and hospital drugs – underpin the Indian company’s growth ambitions, with small-molecule generics remaining the firm’s “bread and butter”.
Kashiv Pharma Swallows Up Adello Biologics, Becoming Kashiv BioSciences
New Jersey-based Kashiv adds biosimilar assets to its repertoire by acquiring Adello Biologics, becoming, in its own words, a “fully-integrated biosciences company with an expanded and dynamic platform for growth.” Adello’s CEO, Chintu Patel, will lead the combination.
Mayne Lines Up Two, But Misses Out On Myring
Sandoz Forms Insulin Biosimilars Deal With Gan & Lee
In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.
Pfizer Receives CHMP Backing On EU Bevacizumab And Withdraws Skinny Label Adalimumab UPDATED
Pfizer was at the forefront of the CHMP’s December 2018 meeting concerning biosimilars, while Dipharma and PARI Pharma were backed on a generic and hybrid medicine apiece.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.